Influence of Plasma Triglyceride Levels on Mitotane Therapeutic Drug Monitoring in Adrenocortical Carcinoma: Translational Implications from a Case Report
International Journal of Translational Medicine · 05.03.2026 · 6 (1) · 11
DOI: 10.3390/ijtm6010011 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Translational Medicine, online erschienen am 05.03.2026. Verfasst von Sonia Fernández-Cañabate und 2 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Mitotane is the cornerstone adjuvant and palliative treatment for adrenocortical carcinoma (ACC), requiring strict therapeutic drug monitoring (TDM) due to its narrow therapeutic window and high inter- and intra-individual pharmacokinetic variability. As a highly lipophilic compound, mitotane may be influenced by plasma lipid levels; however, current TDM protocols do not systematically incorporate lipid profile assessment. We report a case illustrating the clinical impact of hypertriglyceridemia on measured mitotane plasma concentrations.
Methods
We retrospectively analyzed clinical, biochemical, and pharmacokinetic data from a patient with metastatic ACC treated with oral mitotane. Plasma mitotane concentrations were correlated with triglyceride and cholesterol levels using Spearman’s rank correlation analysis.
Results
A 50-year-old male with metastatic ACC experienced abrupt fluctuations in mitotane plasma concentrations despite stable dosing. Supratherapeutic mitotane levels coincided with episodes of marked hypertriglyceridemia. A significant positive correlation was observed between triglyceride levels and plasma mitotane concentrations (ρ = 0.802, p < 0.001), as well as with total cholesterol (ρ = 0.658, p < 0.001).
Conclusions
This case highlights a clinically relevant interaction between triglyceride levels and measured mitotane concentrations. Incorporating routine lipid profile assessment into mitotane TDM protocols may improve interpretation of plasma levels and therapeutic decision-making. Prospective studies are warranted to validate these findings and refine monitoring strategies.
Zitieren
APA
Fernández-Cañabate, S., Díaz-Serrano, A., & Corral-Alaejos, Á. (2026). Influence of Plasma Triglyceride Levels on Mitotane Therapeutic Drug Monitoring in Adrenocortical Carcinoma: Translational Implications from a Case Report. International Journal of Translational Medicine, 6(1), 11. https://doi.org/10.3390/ijtm6010011
Vancouver
Fernández-Cañabate S, Díaz-Serrano A, Corral-Alaejos Á. Influence of Plasma Triglyceride Levels on Mitotane Therapeutic Drug Monitoring in Adrenocortical Carcinoma: Translational Implications from a Case Report. International Journal of Translational Medicine. 2026;6(1):11. doi:10.3390/ijtm6010011
BibTeX
@article{FernndezCaabate2026,
author = {Fernández-Cañabate, Sonia and Díaz-Serrano, Asunción and Corral-Alaejos, Álvaro},
title = {Influence of Plasma Triglyceride Levels on Mitotane Therapeutic Drug Monitoring in Adrenocortical Carcinoma: Translational Implications from a Case Report},
journal = {International Journal of Translational Medicine},
year = {2026},
volume = {6},
number = {1},
pages = {11},
doi = {10.3390/ijtm6010011}
}
EUVIMED